Karen A. Kirby

The paper investigates how the F227C mutation in HIV-1 reverse transcriptase increases susceptibility to islatravir, revealing structural and mechanistic insights into this collateral sensitivity.

The paper investigates how HIV-1 resistance mutations enhance susceptibility to tenofovir by analyzing structural and biochemical changes in reverse transcriptase.

This paper reports cryo-EM structures of HIV-1 RT during PPT strand displacement, revealing the mechanism and key residues involved in the process.

This study reports the crystal structure of HIV-1 reverse transcriptase bound to depulfavirine, showing its extended binding conformation and resistance to common mutations, along with combination efficacy with other antivirals.

The paper characterizes structural, biophysical, and virological properties of HIV-1 capsid-targeting antivirals, showing improved potency and stability through chemical modifications of PF74.

This study investigates how ZW-1261, an FGBP-targeting inhibitor, disrupts HIV-1 capsid morphology by affecting pentameric subunits and core closure.

This paper designs and synthesizes LEN analogs with improved potency against HIV-1 and resistant variants like M66I, showing significant enhancement in antiviral activity.

This paper investigates how HIV capsid core translocates through the Nuclear Pore Complex by analyzing FG repeat interactions and identifies an affinity gradient that facilitates unidirectional translocation.

This paper optimizes Bio-Layer Interferometry (BLI) protocols to measure binding affinities of antiviral compounds with viral proteins, demonstrating sub-nanomolar KD values and covalent interactions.

The paper shows that disrupting HIV-1 integrase interactions with LEDGF/p75 increases antisense RNA (asRNA) production in HIV-1 infected cells.